Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idasanutlin plus Cytarabine in Relapsed/Refractory AML
NCT02545283Phase 3Terminated
- Sponsor
- Roche
- Start
- Dec 2015
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of idasanutlin in acute myeloid leukemia (AML), sponsored by Roche. Started Dec 2015; status: terminated.
02
Drugs
idasanutlin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02545283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02545283.